From GlobeNewswire: 2025-01-03 06:50:00

Eton Pharmaceuticals, Inc. has acquired Galzin, an FDA-approved treatment for Wilson Disease, adding to their rare disease product portfolio. The medication is crucial for less than 5,000 patients in the U.S. with Wilson Disease. Eton plans to begin commercialization in Q1 of 2025, offering the product through their Eton Cares patient support program. They have also acquired European rights to the product. Safety information includes warnings about copper deficiency and gastrointestinal issues. Eton is focused on developing and commercializing treatments for rare diseases, with several products in late-stage development.



Read more at GlobeNewswire: Eton Pharmaceuticals Advances Its Commitment to Rare